Rabbit Monoclonal Antibody Discovery by Single B cell Technology
|
Single B cell technology is a powerful method used to rapidly identify monoclonal antibodies directly from individual B cells. This approach involves isolating single antibody-producing B cells from immunized animals or human donors and then amplifying the genes encoding the antibody's heavy and light chains. These genes are cloned into expression vectors and used to produce recombinant monoclonal antibodies in cell lines.
This method preserves the natural pairing of heavy and light chains, ensuring the authenticity and functionality of the antibodies. Compared to traditional hybridoma methods, single B cell technology is faster, more efficient, and particularly useful for generating antibodies against complex or weakly immunogenic targets. |
Talk with our scientist about your unique project!
|
Fig. Brief Explanation of the Workflow of Single B cell technology for mAb Discovery
Hybridoma vs. Single B Cell Technology
Hybridoma technology involves fusing antibody-producing B cells from an immunized animal (usually a mouse) with immortal myeloma cells to create hybrid cells that can continuously produce monoclonal antibodies. While well-established, this method is time-consuming, often limited to murine antibodies. Also, this medhod request much more animals to be immunized to harvest a large amount of clones which is not following 3R principle in animal usage.
In contrast, single B cell technology isolates individual antigen-specific B cells directly from immunized animals or human donors without cell fusion. Therefore, an extended animal species can be used for monoclonal antibody discovery such as rabbit, dog, cat, etc. The native heavy and light chain genes are amplified using RT-PCR and expressed recombinantly, preserving natural pairing and enabling rapid identification of fully functional monoclonal antibodies. This method is faster, more scalable, and compatible with multiple species—including humans—making it ideal for modern therapeutic and diagnostic antibody discovery.
Hybridoma technology involves fusing antibody-producing B cells from an immunized animal (usually a mouse) with immortal myeloma cells to create hybrid cells that can continuously produce monoclonal antibodies. While well-established, this method is time-consuming, often limited to murine antibodies. Also, this medhod request much more animals to be immunized to harvest a large amount of clones which is not following 3R principle in animal usage.
In contrast, single B cell technology isolates individual antigen-specific B cells directly from immunized animals or human donors without cell fusion. Therefore, an extended animal species can be used for monoclonal antibody discovery such as rabbit, dog, cat, etc. The native heavy and light chain genes are amplified using RT-PCR and expressed recombinantly, preserving natural pairing and enabling rapid identification of fully functional monoclonal antibodies. This method is faster, more scalable, and compatible with multiple species—including humans—making it ideal for modern therapeutic and diagnostic antibody discovery.
Fig. Brief Comparison of mAb Discovery Strategies
Credit: Single B cell technologies for monoclonal antibody discovery, Pedrioli, Alessandro et al., Trends in Immunology, Volume 42, Issue 12, 1143 - 1158
Credit: Single B cell technologies for monoclonal antibody discovery, Pedrioli, Alessandro et al., Trends in Immunology, Volume 42, Issue 12, 1143 - 1158
Casy Study - Single B Cell Rabbit Monoclonal Antibody Discovery
|
Case Study 1 - Small Molecular (Hapten) Rabbit mAb
Developing monoclonal antibodies against small molecules (haptens) presents unique challenges due to their low immunogenicity and the need for high specificity. However, after immunization the small molecule-specific B cells are often rare amoung immune cells. Single B cell screening allows direct isolation and analysis of these rare populations, increasing the likelihood of capturing high-affinity clones. |
|
Case Study 2 - Protein Antigen and Immunofluorescent Application
Single B cell technology is particularly advantageous for developing high-performance monoclonal antibodies used in immunofluorescent assays (IFA), where sensitivity and specificity are critical. Especially the epitope since the target proteins are often in their native cellular context in IFA assays.
Single B cell technology is particularly advantageous for developing high-performance monoclonal antibodies used in immunofluorescent assays (IFA), where sensitivity and specificity are critical. Especially the epitope since the target proteins are often in their native cellular context in IFA assays.
|
Welcome to talk with our scientist for your specific project! Click the button to send us an email, or directly from your email app to: [email protected].
|
